Autologous Stem Cell Transplant for Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
While primary central nervous lymphoma (PCNSL) is sensitive to methotrexate chemotherapy, more than half of patients will relapse within five years. Autologous stem-cell transplant (ASCT) is increasingly used as consolidative treatment. This systematic review and meta-analysis provides estimates for response and survival after ASCT and suggests improved rates compared to the historical data.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Iyad Alnahhas, Mohammad Jawish, Mouaz Alsawas, Alicia Zukas, Larry Prokop, M. Hassan Murad, Mark Malkin Source Type: research
More News: Chemotherapy | Hematology | History of Medicine | Leukemia | Lymphoma | Methotrexate | Myeloma | Primary CNS Lymphoma | Stem Cell Therapy | Stem Cells | Transplants